Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

Abstract

FOLFIRINOX with RIO showed acceptable toxicity and promising efficacy for GEM-refractory unresectable PC. However, this treatment requires careful observation of treatment-related hematologic toxicities.